This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.62% per year. These returns cover a period from January 1, 1988 through June 2, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
broker-rating: Archive
Brokers Suggest Investing in AGNC Investment (AGNC): Read This Before Placing a Bet
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in AGNC Investment (AGNC). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
AGNCNegative Net Change
broker-rating earnings-estimates-revisions earnings-growth
Is It Worth Investing in Veeva (VEEV) Based on Wall Street's Bullish Views?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Veeva (VEEV). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
VEEVPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Is JD.com (JD) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
The average brokerage recommendation (ABR) for JD.com (JD) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
JDNegative Net Change
broker-rating earnings-estimates-revisions earnings-growth
Is It Worth Investing in CyberArk (CYBR) Based on Wall Street's Bullish Views?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), CyberArk (CYBR) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
CYBRPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
MongoDB (MDB) Is Considered a Good Investment by Brokers: Is That True?
by Zacks Equity Research
The average brokerage recommendation (ABR) for MongoDB (MDB) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
MDBPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Wall Street Bulls Look Optimistic About GigaCloud Technology Inc. (GCT): Should You Buy?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in GigaCloud Technology Inc. (GCT). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
GCTNegative Net Change
broker-rating earnings-estimates-revisions earnings-growth
Brokers Suggest Investing in PDD Holdings Inc. Sponsored ADR (PDD): Read This Before Placing a Bet
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), PDD Holdings Inc. Sponsored ADR (PDD) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
PDDNegative Net Change
broker-rating earnings-estimates-revisions earnings-growth
Is CRISPR Therapeutics (CRSP) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), CRISPR Therapeutics (CRSP) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
CRSPPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Wall Street Bulls Look Optimistic About Dorian LPG (LPG): Should You Buy?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Dorian LPG (LPG). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
LPGPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Should You Invest in Zoetis (ZTS) Based on Bullish Wall Street Views?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Zoetis (ZTS) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
ZTSPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Should You Invest in Axon (AXON) Based on Bullish Wall Street Views?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Axon (AXON). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
AXONPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Should You Invest in VICI Properties (VICI) Based on Bullish Wall Street Views?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), VICI Properties (VICI) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
VICIPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Is Affirm Holdings (AFRM) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Affirm Holdings (AFRM). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
AFRMPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Is Astrazeneca (AZN) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Astrazeneca (AZN) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
AZNNegative Net Change
broker-rating earnings-estimates-revisions earnings-growth
Brokers Suggest Investing in Diebold Nixdorf, Incorporated (DBD): Read This Before Placing a Bet
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Diebold Nixdorf, Incorporated (DBD). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
DBDPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Dell Technologies (DELL) Is Considered a Good Investment by Brokers: Is That True?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Dell Technologies (DELL) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
DELLPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Wall Street Analysts See Intuitive Surgical (ISRG) as a Buy: Should You Invest?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Intuitive Surgical (ISRG) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
ISRGPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Brokers Suggest Investing in Bitfarms (BITF): Read This Before Placing a Bet
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Bitfarms (BITF) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
BITFPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Is It Worth Investing in Archrock Inc. (AROC) Based on Wall Street's Bullish Views?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Archrock Inc. (AROC) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
AROCNegative Net Change
broker-rating earnings-estimates-revisions earnings-growth
Is It Worth Investing in Ardmore Shipping (ASC) Based on Wall Street's Bullish Views?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Ardmore Shipping (ASC) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
ASCPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Brokers Suggest Investing in Ero Copper (ERO): Read This Before Placing a Bet
by Zacks Equity Research
The average brokerage recommendation (ABR) for Ero Copper (ERO) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
ERONegative Net Change
broker-rating earnings-estimates-revisions earnings-growth
Newmont (NEM) Is Considered a Good Investment by Brokers: Is That True?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Newmont (NEM) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
NEMNegative Net Change
broker-rating earnings-estimates-revisions earnings-growth
Wall Street Bulls Look Optimistic About AeroVironment (AVAV): Should You Buy?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in AeroVironment (AVAV). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
AVAVNegative Net Change
broker-rating earnings-estimates-revisions earnings-growth
Brokers Suggest Investing in Halliburton (HAL): Read This Before Placing a Bet
by Zacks Equity Research
The average brokerage recommendation (ABR) for Halliburton (HAL) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
HALNegative Net Change
broker-rating earnings-estimates-revisions earnings-growth
Is Alibaba (BABA) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Alibaba (BABA) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
BABANegative Net Change
broker-rating earnings-estimates-revisions earnings-growth